For people with vitiligo and their caregivers
What this page helps you do
Learn what off-label pimecrolimus use means and why its evidence is limited. Review its strongest warning and what to ask if light therapy is also planned.
- Your task
- Understand the current definition, evidence boundary, practical burden, and questions that affect fit.
- The clinician boundary
- Diagnosis, assessment of activity and body sites, prescribing, monitoring, and personalized treatment decisions belong to a qualified clinician.
Why was I offered pimecrolimus if it is not approved for vitiligo?
In the United States, pimecrolimus cream is approved for specified atopic dermatitis use, not vitiligo, so using it for vitiligo is off-label. Clinicians may still offer an off-label medicine when they judge the broader evidence relevant. Elidel is a brand name; the current label for the exact product you receive still matters. Evidence Evidence Evidence
Why this matters
Elidel (pimecrolimus) is a calcineurin inhibitor, a non-steroid cream that calms the local immune response. Guidelines discuss this drug class. Elidel and Protopic (tacrolimus) still do not have the same evidence and are not interchangeable.
What are realistic expectations for my patches?
Pooled evidence for topical calcineurin inhibitors, alone and with phototherapy, reports group-level outcomes that vary by body area. Because studies differ and pool multiple medicines, it cannot establish pimecrolimus-specific benefit or show that pimecrolimus works like tacrolimus. Evidence Evidence
Why this matters
Systematic reviews include pimecrolimus within a wider medicine class. Guidelines treat the evidence as support for discussing an option—not proof that one medicine is better than another.
What should I know about the boxed warning and skin reactions?
The US pimecrolimus label carries the FDA’s strongest safety alert. This is called a “boxed warning.” It notes rare cancer reports but says the medicine has not been proven to cause them. It warns against continuous long-term use. Burning can occur where you apply it. Evidence
Why this matters
The boxed warning and Medication Guide should be part of your decision. The label also addresses infections, immune status, lymph-node changes, and other situations that require clinical attention.
What if I am also using or considering phototherapy?
Tell both the prescriber and phototherapy team. The pimecrolimus label tells patients to minimize or avoid natural and artificial sunlight, including ultraviolet treatment, while vitiligo guidelines discuss selected clinician-supervised combinations. That conflict needs an explicit, coordinated answer; it is not permission to combine them on your own. Evidence Evidence Evidence
Why this matters
Regulatory labels and clinical guidelines have different roles, and both belong in your decision. The label warning matters before you assume that two separately discussed options are automatically safe together.
Questions that can change the next decision
- For your clinicianHow does the ultraviolet warning affect my plan?Saving keeps this on your device and needs JavaScript, which is off in this browser.
- For your clinicianHave both teams agreed on one set of instructions?Saving keeps this on your device and needs JavaScript, which is off in this browser.
Evidence and update context
This optional layer shows the evidence boundary reviewed for this page as of 2026-08-03.
- What this evidence supports
- Elidel (pimecrolimus) is a calcineurin inhibitor, a non-steroid cream that calms the local immune response. Guidelines discuss this drug class. Elidel and Protopic (tacrolimus) still do not have the same evidence and are not interchangeable.
- What it does not establish
- Off-label use depends on clinical judgment and is not a regulator-reviewed vitiligo indication. Your age, immune status, body area, other medicines, and the exact formulation can change whether it fits you.
Applicability check
Who was studied?
These fields show what the cited evidence reports about the people and body sites behind outcome or safety claims. “Not reported” means the reviewed source omitted the field; “Pending exact source review” means SteadySkin has not made that determination yet.
Pooled evidence for topical calcineurin inhibitors, alone and with phototherapy, reports group-level outcomes that vary by body area. Because studies differ and pool multiple medicines, it cannot establish pimecrolimus-specific benefit or show that pimecrolimus works like tacrolimus.
- Age range
- Pending exact source review
- Condition subtype
- Pending exact source review
- Severity or extent
- Pending exact source review
- Sample size
- Pending exact source review
- Geography and care setting
- Pending exact source review
- Skin tone or phototype
- Pending exact source review
- Race
- Pending exact source review
- Ethnicity
- Pending exact source review
- Body sites
- Pending exact source review
What that means for this page: The claim is explicitly gated as body-site evidence, but exact population and site extraction is still pending. It cannot publish or support transfer of one site’s result to another site until that review is complete.
The US pimecrolimus label carries the FDA’s strongest safety alert. This is called a “boxed warning.” It notes rare cancer reports but says the medicine has not been proven to cause them. It warns against continuous long-term use. Burning can occur where you apply it.
- Age range
- Pending exact source review
- Condition subtype
- Pending exact source review
- Severity or extent
- Pending exact source review
- Sample size
- Pending exact source review
- Geography and care setting
- Pending exact source review
- Skin tone or phototype
- Pending exact source review
- Race
- Pending exact source review
- Ethnicity
- Pending exact source review
- Body sites
- Pending exact source review
What that means for this page: This is explicitly gated as a safety claim, but exact population extraction is still pending. It cannot publish or support an estimate of individual risk until that review is complete.
Tell both the prescriber and phototherapy team. The pimecrolimus label tells patients to minimize or avoid natural and artificial sunlight, including ultraviolet treatment, while vitiligo guidelines discuss selected clinician-supervised combinations. That conflict needs an explicit, coordinated answer; it is not permission to combine them on your own.
- Age range
- Pending exact source review
- Condition subtype
- Pending exact source review
- Severity or extent
- Pending exact source review
- Sample size
- Pending exact source review
- Geography and care setting
- Pending exact source review
- Skin tone or phototype
- Pending exact source review
- Race
- Pending exact source review
- Ethnicity
- Pending exact source review
- Body sites
- Pending exact source review
What that means for this page: This is explicitly gated as a safety claim, but exact population extraction is still pending. It cannot publish or support an estimate of individual risk until that review is complete.
Evidence behind this page
Sources
Each evidence badge opens the source and its limits. The full list stays available here.
- DailyMed, U.S. National Library of MedicineRegulatory / guideline · not independentRelevant relationship disclosed
- Published
- 2026-04-30
- SteadySkin last checked
- 2026-07-31
What this source can and cannot tell you
Why the independence label says this: The National Library of Medicine hosts DailyMed. The product company submits the label to FDA, so it is authoritative for product labeling but not independent efficacy evidence.
What this source supports
Supports the US atopic-dermatitis indication, boxed warning, application-site effects, long-term-use precaution and instructions to avoid ultraviolet treatment and minimize natural or artificial sunlight.
What it does not support
It does not approve pimecrolimus for vitiligo, establish vitiligo efficacy or resolve off-label guideline discussion of supervised combinations.
Automated draft claim mapping withheld from reader-facing evidence details until clinical or editorial review is recorded. This page is not yet approved for indexing.
- JAMA Dermatology (Lee JH, et al.)Clinical research · independentIndependent source
- Published
- 2019-05-29
- SteadySkin last checked
- 2026-07-31
What this source can and cannot tell you
What this source supports
Supports pooled group-level repigmentation outcomes for topical calcineurin inhibitors alone and with phototherapy, including variation by body area.
What it does not support
Considerable study heterogeneity limits product-specific and individual inference, and the review does not override current product labels or prove one medicine superior.
Automated draft claim mapping withheld from reader-facing evidence details until clinical or editorial review is recorded. This page is not yet approved for indexing.
- Journal of the European Academy of Dermatology and VenereologyRegulatory / guideline · not independentRelevant relationship disclosed
- Published
- 2023-09-25
- SteadySkin last checked
- 2026-07-31
What this source can and cannot tell you
Why the independence label says this: The journal is the publisher. This label refers to extensive author relationships disclosed for the recommendation, not to the journal itself.
What this source supports
It supports current expert-consensus terminology, clinical assessment, disease-activity evaluation, treatment-goal discussion, and shared decision-making.
What it does not support
It is not independent comparative proof. It cannot diagnose a reader from a description or photograph.
Automated draft claim mapping withheld from reader-facing evidence details until clinical or editorial review is recorded. This page is not yet approved for indexing.
- British Journal of Dermatology (Eleftheriadou V, et al.)Regulatory / guideline · independentIndependent source
- Published
- 2022-01-01
- SteadySkin last checked
- 2026-07-31
What this source can and cannot tell you
What this source supports
Supports the clinical history and assessment domains, evaluation of associated autoimmune conditions, its recommendation for thyroid function and antithyroid antibody screening, current classification context, treatment-option map, psychosocial assessment, medical photography and the limits of pediatric evidence.
What it does not support
It was designed for UK care and reviewed literature through May 2019; it does not establish a universal testing plan, prescribe an individual plan, or establish current US labeling or coverage.
Automated draft claim mapping withheld from reader-facing evidence details until clinical or editorial review is recorded. This page is not yet approved for indexing.